Skip to content
TriangleGet started
← Aggressive B-Cell Non-Hodgkin Lymphoma

HEALTH PROFESSIONAL · SOURCE READING

Rituximab plus lenalidomide

Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 12, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.

Context: Treatment of Aggressive, Recurrent B-Cell Non-Hodgkin Lymphoma / Treatment Options for Aggressive, Recurrent B-Cell Non-Hodgkin Lymphoma

Evidence (rituximab plus lenalidomide):

In two phase II trials, 49 patients showed a 19% to 35% overall response rate to lenalidomide with rituximab.[45,46][Level of evidence C3]

Source links and citations

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Independent clinical review pending · Not medical advice